MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant
about
Recent advances in the development of vaccines for tuberculosisPostulates for validating TLR4 agonistsTrial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapyCharacterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-O-acylated lipooligosaccharideA structure-function approach to optimizing TLR4 ligands for human vaccinesTLR4 ligands lipopolysaccharide and monophosphoryl lipid a differentially regulate effector and memory CD8+ T Cell differentiation.Trial Watch: Toll-like receptor agonists in oncological indications.IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF.The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.Gene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant.Nonbilayer Phospholipid Arrangements Are Toll-Like Receptor-2/6 and TLR-4 Agonists and Trigger Inflammation in a Mouse Model Resembling Human Lupus.Modulation of Innate Immune Responses via Covalently Linked TLR Agonists.In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant.Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strainTrial Watch: Immunotherapy plus radiation therapy for oncological indications.A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.Three conserved MyD88-recruiting TLR residues exert different effects on the human TLR4 signaling pathway.Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines Against Mycobacterium tuberculosis.Old and new adjuvants.IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice.Protein nanovaccine confers robust immunity against Toxoplasma.Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate TB Subunit Vaccine.Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses
P2860
Q26796440-21D5F475-0C45-4F64-A4AC-8E7163F57113Q27023992-BF5B9F88-7270-48C4-95BD-077FE258247AQ28067939-C04F8EAB-849F-4279-84E9-EB41E2BA441FQ28538989-360463B1-A0D2-41EF-AE15-CE578136DAE4Q28818147-41F2F71F-A2A5-46C5-A12E-1BC7EA5E9155Q33807405-025DED8F-6E1E-48EF-B0E8-7B1ADA64FCCCQ33878578-F60E4063-9706-4B97-B5AC-7D0ABB947191Q34400813-1E80998B-99AA-4E56-A21F-3AD3CB2D81DDQ35695840-A90108A0-E438-4AC8-B09C-DF71DEC3BC56Q35885464-9824E5CD-D25E-43B2-86D5-4781669FC822Q35886513-A9ADA210-4397-47E4-BEBB-9C5856DA0367Q36237416-5764A959-DC1E-44F0-A357-D4853CBAD3DCQ36333881-443C4651-7759-42BD-84DB-EBA1A8E69090Q37001755-C250E548-953B-43A0-8429-35CC69F7F64BQ37295244-5A2910AA-C637-4095-AEC5-342740D109F1Q37308207-76E992FF-55D1-4B06-B9FC-016E6FFA8E64Q37431320-C74D7D59-A394-442B-ABD4-2767477185D0Q37641418-92EC5A1F-484B-4CC8-A089-35BE5E8ACD74Q38878334-BD3A0684-6C4D-4E2B-A03B-3EAFEFEF925FQ38907507-4CEF7721-B91A-4B31-B6CE-8FB4F0AFCCCBQ39451745-36D565C5-7BD9-4E3D-BBDA-82CC9D67F399Q40476014-87ACE60C-045C-4F1D-AAE4-EA287A14EFABQ40517477-9C26C979-50E6-42E6-A80B-C2E5BEA83749Q47102683-7224DD49-CBC9-4F10-A5A1-79158A161DCBQ52655238-2FDCC54C-26BB-4B18-AC7A-9157FE48A6A5Q54234703-6F14B43E-1F2F-4FBE-B811-31E785A582DAQ55691134-4BE4C0A3-1F4F-487F-A379-D72EED5B8399Q56944933-C3F2E0CD-CAEC-49F6-A4F5-90637A6A10C2
P2860
MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MyD88 and TRIF synergistic int ...... ynthetic TLR4 agonist adjuvant
@en
MyD88 and TRIF synergistic int ...... nthetic TLR4 agonist adjuvant.
@nl
type
label
MyD88 and TRIF synergistic int ...... ynthetic TLR4 agonist adjuvant
@en
MyD88 and TRIF synergistic int ...... nthetic TLR4 agonist adjuvant.
@nl
prefLabel
MyD88 and TRIF synergistic int ...... ynthetic TLR4 agonist adjuvant
@en
MyD88 and TRIF synergistic int ...... nthetic TLR4 agonist adjuvant.
@nl
P2093
P2860
P50
P356
P1476
MyD88 and TRIF synergistic int ...... ynthetic TLR4 agonist adjuvant
@en
P2093
Anthony L Desbien
Elyse A Lucas
Hillarie Plessner Windish
Jeffrey A Guderian
Malcolm S Duthie
Rhea N Coler
Thomas E Hudson
P2860
P304
P356
10.1002/EJI.201243124
P407
P577
2013-07-03T00:00:00Z